X4 Pharmaceuticals (XFOR) Other Operating Expenses (2017 - 2024)
X4 Pharmaceuticals' (XFOR) quarterly Other Operating Expenses came in at $105.0 million in Q2 2024, up 20728.68% quarter-over-quarter from -$509000.0 in Q4 2022.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Other Operating Expenses (2017 - 2024) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Other Operating Expenses for 4 consecutive years, with $105.0 million the latest figure, recorded in Q2 2024.
- For the quarter ending Q2 2024, Other Operating Expenses changed N/A year-over-year to $105.0 million; the trailing twelve-month figure through Mar 2025 stood at $105.0 million (changed N/A YoY), and the FY2024 full-year result was $105.0 million, changed N/A from the prior year.
- Other Operating Expenses climbed to $105.0 million in Q2 2024 per XFOR's latest filing, from -$509000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $105.0 million in Q2 2024 and bottomed at -$509000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 105.00 Mn |
| Dec 31, 2022 | -509,000.00 |
| Mar 31, 2022 | 509,000.00 |
| Dec 31, 2019 | 104,000.00 |
| Sep 30, 2019 | -4.00 Mn |
| Dec 31, 2017 | 13.89 Mn |